kenyboy, Amarin has a patent for hypertriglyceridemia which is (150-499 mg/dl) which was approved for CVE. Hikma received their approval for the SH severe hypertriglyceridemia (>500 mg/dl) and carved out the CVE (150-499). Your Opinion below states the opposite. "concluding that Hikma’s generic product—approved only for the treatment of hypertriglyceridemia" from the 1st paragraph below. AI got that wrong.
“affirmed”, not “reversed”, your last paragraph. Further, S. Court is reviewing judgment of CAFC, not that of District Court. Your hypothetical opinion of Supreme Court fails to even mention CAFC except in that last paragraph.
Market Data 
Markets 
AI
